This site is intended for U.S. Healthcare Professionals only.

  • U.S. Full Prescribing Information |
  • Medication Guide |
  • Indication

    Indication

    SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

    Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

Getting started

Resources for your practice

We’re working to support eligible patients to access their medication by offering affordability and individualized assistance.

Forms for your practice:

Start Icon

START

START

Enroll patients with the Start Form

Complete and submit the SOTYKTU Start Form to assist patients in starting on SOTYKTU.

SOTYKTU 360 Support. Your circle of support Logo
Program enrollment form

SOTYKTU PATIENT SUPPORT PROGRAM START FORM HOW-TO GUIDE

Download How-To Guide

Free Trial Offer

SEE INFORMATION

PATIENT AUTHORIZATION AND AGREEMENT (PAA) FORM

Stay Icon

STAY

STAY

SOTYKTU Bridge Program

Eligible, commercially insured patients may access SOTYKTU for up to 3 years if there is a delay or denial during the insurance coverage determination process.

BRIDGE PROGRAM TERMS AND
CONDITIONS

SEE INFORMATION

CoverMyMeds® PORTAL
USER GUIDE

Download overview

Access Template Letters

The access template letters (Formulary Exception, Medical Necessity, Reverification Letter, Appeals, Alternative Funding Program Appeal) are provided to assist you in helping your appropriate patients gain access to treatment with SOTYKTU.

Save  Icon

SAVE

SAVE

SOTYKTU Co-Pay Assistance Program

Eligible, commercially insured patients may pay as little as $0 per month for SOTYKTU with the SOTYKTU Co-Pay Assistance Card.

CO-PAY TERMS AND CONDITIONS

SEE INFORMATION

ACCESS AND REIMBURSEMENT GUIDE

Download Guide

Need materials to support your patients?
Visit the patient resources page to see what is available.
A SOTYKTU™ (deucravacitinib) patient - man

Video: Peer Perspectives

Watch a video on SOTYKTU Peer Perspectives: Clearer Choice
Study Design And Co-primary Endpoints Thumbnail
Efficacy Thumbnail
Safety (week 16 and 52) Thumbnail
MOA And Selectivity Thumbnail
Dosing And Laboratory Evaluation Thumbnail
Important Safety Information Thumbnail

Watch a video on SOTYKTU Peer Perspectives: Clearer Choice
Study Design And Co-primary Endpoints Thumbnail
Efficacy Thumbnail
Safety (week 16 and 52) Thumbnail
MOA And Selectivity Thumbnail
Dosing And Laboratory Evaluation Thumbnail
Important Safety Information Thumbnail
Bristol Myers Squibb™ Logo

SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU
logo
are trademarks of Bristol-Myers Squibb Company.

Otezla is a registered trademark of Amgen Inc.

© 2023 Bristol-Myers Squibb Company.

1787-US-2300483 07/23